Neurotensin expression and outcome of malignant pleural mesothelioma

Biochimie

Volumn 92, Issue 2, 2010, Pages 164-170

  Alifano, Marco ^a   Loi, Mauro ^a   Camilleri Broet, Sophie ^b,c   Dupouy, Sandra ^d   Régnard, Jean François ^a   Forgez, Patricia ^d  

^a HÔTEL DIEU   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c Cabinet de Pathologie Tolbiac   (France)

^d HÔPITAL SAINT ANTOINE   (France)

Author keywords

Cancer progression; Cellular migration; Malignant pleural mesothelioma; Neurotensin; Prognosis biomarker

Indexed keywords

CISPLATIN; COLLAGEN; NEUROTENSIN; NEUROTENSIN RECEPTOR; PEMETREXED;

AGED; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INVASION; CANCER SURVIVAL; CELL INVASION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG SURGERY; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; PLEURA MESOTHELIOMA; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL TIME; WOUND HEALING;

AGED; CELL LINE, TUMOR; CELL MOVEMENT; COLLAGEN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MESOTHELIOMA; NEOPLASM INVASIVENESS; NEUROTENSIN; PLEURAL NEOPLASMS; PROGNOSIS; RECEPTORS, NEUROTENSIN; SURVIVAL ANALYSIS;

EID: 74249110540     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2009.11.004     Document Type: Article

References (26)

1. Boutin C., Schlesser M., Frenay C., and Astoul P. Malignant pleural mesothelioma. Eur. Respir. J. 12 (1998) 972-981
2. Goldberg M., Imbernon E., Rolland P., Gilg S., Saves I.M., de Q.A., Frenay C., Chamming's S., Arveux P., Boutin C., Launoy G., Pairon J.C., Astoul P., Galateau-Salle F., and Brochard P. The French national mesothelioma surveillance program. Occup. Environ. Med 63 (2006) 390-395
3. Peto J., Decarli A., La V.C., Levi F., and Negri E. The European mesothelioma epidemic. Br. J. Cancer 79 (1999) 666-672
4. Chapman A., Mulrennan S., Ladd B., and Muers M.F. Population based epidemiology and prognosis of mesothelioma in Leeds, UK. Thorax 63 (2008) 435-439
5. Vogelzang N.J., Rusthoven J.J., Symanowski J., Denham C., Kaukel E., Ruffie P., Gatzemeier U., Boyer M., Emri S., Manegold C., Niyikiza C., and Paoletti P. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 21 (2003) 2636-2644
6. Hazarika M., White Jr. R.M., Booth B.P., Wang Y.C., Ham D.Y., Liang C.Y., Rahman A., Gobburu J.V., Li N., Sridhara R., Morse D.E., Lostritto R., Garvey P., Johnson J.R., and Pazdur R. Pemetrexed in malignant pleural mesothelioma. Clin. Cancer Res. 11 (2005) 982-992
7. Ceresoli G.L., Gridelli C., and Santoro A. Multidisciplinary treatment of malignant pleural mesothelioma. Oncologist 12 (2007) 850-863
8. Sugarbaker D.J., Flores R.M., Jaklitsch M.T., Richards W.G., Strauss G.M., Corson J.M., DeCamp Jr. M.M., Swanson S.J., Bueno R., Lukanich J.M., Baldini E.H., and Mentzer S.J. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J. Thorac. Cardiovasc. Surg. 117 (1999) 54-63
9. Flores R.M., Krug L.M., Rosenzweig K.E., Venkatraman E., Vincent A., Heelan R., Akhurst T., and Rusch V.W. Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. J. Thorac. Oncol. 1 (2006) 289-295
10. Batirel H.F., Metintas M., Caglar H.B., Yildizeli B., Lacin T., Bostanci K., Akgul A.G., Evman S., and Yuksel M. Trimodality treatment of malignant pleural mesothelioma. J. Thorac. Oncol. 3 (2008) 499-504
11. Weder W., Kestenholz P., Taverna C., Bodis S., Lardinois D., Jerman M., and Stahel R.A. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J. Clin. Oncol. 22 (2004) 3451-3457
12. Weder W., Stahel R.A., Bernhard J., Bodis S., Vogt P., Ballabeni P., Lardinois D., Betticher D., Schmid R., Stupp R., Ris H.B., Jermann M., Mingrone W., Roth A.D., and Spiliopoulos A. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann. Oncol. 18 (2007) 1196-1202
13. Evers B.M. Neurotensin and growth of normal and neoplastic tissues. Peptides 27 (2006) 2424-2433
14. Castagliuolo I., Wang C.C., Valenick L., Pasha A., Nikulasson S., Carraway R.E., and Pothoulakis C. Neurotensin is a proinflammatory neuropeptide in colonic inflammation. J. Clin. Invest. 103 (1999) 843-849
15. Brun P., Mastrotto C., Beggiao E., Stefani A., Barzon L., Sturniolo G.C., Palu G., and Castagliuolo I. Neuropeptide neurotensin stimulates intestinal wound healing following chronic intestinal inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 288 (2005) G621-G629
16. Elek J., Pinzon W., Park K.H., and Narayanan R. Relevant genomics of neurotensin receptor in cancer. Anticancer Res. 20 (2000) 53-58
17. Dupouy S., Viardot-Foucault V., Alifano M., Souaze F., Plu-Bureau, Chaouat M., Lavaur A., Hugol D., Gespach C., Gompel A., and Forgez P. The neurotensin receptor-1 pathway contributes to human ductal breast cancer progression. PLoS One 4 (2009) e423
18. Shimizu S., Tsukada J., Sugimoto T., Kikkawa N., Sasaki K., Chazono H., Hanazawa T., Okamoto Y., and Seki N. Identification of a novel therapeutic target for head and neck squamous cell carcinomas: a role for the neurotensin-neurotensin receptor 1 oncogenic signaling pathway. Int. J. Cancer 123 (2008) 1816-1823
19. Rihn B.H., Mohr S., McDowell S.A., Binet S., Loubinoux J., Galateau F., Keith G., and Leikauf G.D. Differential gene expression in mesothelioma. FEBS Lett. 480 (2000) 95-100
20. Souaze F., Dupouy S., Viardot-Foucault V., Bruyneel E., Attoub S., Gespach C., Gompel A., and Forgez P. Expression of neurotensin and NT1 receptor in human breast cancer: a potential role in tumor progression. Cancer Res. 66 (2006) 6243-6249
21. Janne P.A., Taffaro M.L., Salgia R., and Johnson B.E. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res. 62 (2002) 5242-5247
22. Zhang X., Varin E., Briand M., Allouche S., Heutte N., Schwartz L., Poulain L., and Icard P. Novel therapy for malignant pleural mesothelioma based on anti-energetic effect: an experimental study using 3-Bromopyruvate on nude mice. Anticancer Res. 29 (2009) 1443-1448
23. Souaze F., Rostene W., and Forgez P. Neurotensin agonist induces differential regulation of neurotensin receptor mRNA. Identification of distinct transcriptional and post-transcriptional mechanisms. J. Biol. Chem. 272 (1997) 10087-10094
24. Toy-Miou-Leong M., Bachelet C.M., Pelaprat D., Rostene W., and Forgez P. NT agonist regulates expression of nuclear high-affinity neurotensin receptors. J. Histochem. Cytochem. 52 (2004) 335-345
25. Wang X., Wang Q., Ives K.L., and Evers B.M. Curcumin inhibits neurotensin-mediated interleukin-8 production and migration of HCT116 human colon cancer cells. Clin. Cancer Res. 12 (2006) 5346-5355
26. Galffy G., Mohammed K.A., Dowling P.A., Nasreen N., Ward M.J., and Antony V.B. Interleukin 8: an autocrine growth factor for malignant mesothelioma. Cancer Res. 59 (1999) 367-371